Postscript

ABSTRACT

This chapter reveals some of the major changes in the European and UK regulatory framework following the UK leaving the EU (Brexit), public health consequences of the supply of infected blood products, and the Covid-19 pandemic. It covers issues that occurred after Brexit, the independent medicines and medical devices safety review, and the UK blood enquiry. It also mentions the Medicines and Healthcare products Regulatory Agency (MHRA) that became the UK’s standalone regulator of medicines and medical devices since 1 January 2021, acting independently in joint work with other international regulators. The chapter elaborates on the UK’s intention to develop a new regulatory framework for medical devices that reflect the Independent Medicines and Medical Devices Safety Review published in July 2020. It highlights the European Medicines Agency’s (EMA) cooperation with the World Health Organization (WHO) on developing potential Covid-19 treatments by facilitating large-scale clinical trials. © Oxford University Press 2021.